Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Importer's Entry Notice, 14255-14256 [2014-05516]
Download as PDF
Federal Register / Vol. 79, No. 49 / Thursday, March 13, 2014 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–1423]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Importer’s Entry
Notice
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by April 14,
2014.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0046. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 1350 Piccard
Dr., PI50–400B, Rockville, MD 20850,
PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
TKELLEY on DSK3SPTVN1PROD with NOTICES
SUMMARY:
Importer’s Entry Notice—(OMB Control
Number 0910–0046)—Extension
Section 801 of the Federal Food, Drug,
and Cosmetic Act (the FD&C Act) (21
U.S.C. 381) charges the Secretary of
Health and Human Services, through
FDA, with the responsibility of assuring
foreign-origin, FDA-regulated foods,
drugs, cosmetics, medical devices,
radiological health, and tobacco
products offered for import into the
United States meet the same
requirements of the FD&C Act as do
domestic products, and for preventing
VerDate Mar<15>2010
17:33 Mar 12, 2014
Jkt 232001
products from entering the country if
they are not in compliance. The
discharge of this responsibility involves
close coordination and cooperation
between FDA headquarters and field
inspectional personnel and the U.S.
Customs Service (USCS), as the USCS is
responsible for enforcing the revenue
laws covering the very same products.
This collection of information gathers
data for FDA-regulated products being
imported into the United States and is
being used by FDA to review and
prevent imported products from
entering the United States if the
products do not meet the same
requirements of the FD&C Act as
domestic products.
Until October 1995, importers were
required to file manual entries on OMBapproved forms that were accompanied
by related documents. FDA did away
with use of the paper forms effective
October 1, 1995, to eliminate duplicity
of information and to reduce the
paperwork burden both on the import
community and FDA. FDA then
implemented an automated nationwide
entry processing system, which enabled
FDA to more efficiently obtain and
process the information it requires to
fulfill its regulatory responsibility.
Most of the information FDA requires
to carry out its regulatory
responsibilities under section 801 is
already provided electronically by filers
to USCS. Because USCS relays this data
to FDA using an electronic interface, the
majority of data submitted by the entry
filer need be completed only once.
At each U.S. port of entry (seaport,
landport, and airport) where foreignorigin, FDA-regulated products are
offered for import, FDA is notified
through USCS’s Automated Commercial
System (ACS) by the importer (or his/
her agent) of the arrival of each entry.
Following such notification, FDA
reviews relevant data to ensure the
imported product meets the standards
as required for domestic products,
decides on the admissibility of the
imported product, and informs the
importer and USCS of its decision. A
single entry frequently contains
multiple lines of different products.
FDA may authorize products listed on
specific lines to enter the United States
unimpeded, while other products listed
in the same entry may be held pending
further FDA review/action.
All entry data pass through a
screening criteria program resident on a
USCS computer. This screening
program was developed and is
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
14255
maintained by FDA. This electronic
screening criteria module makes the
initial screening decision on every entry
of foreign-origin, FDA-regulated
product. Almost instantaneously after
the entry is filed, the filer receives
FDA’s admissibility decision for each
entry, i.e., ‘‘MAY PROCEED’’ or ‘‘FDA
REVIEW.’’
In addition to the information
collected by USCS, FDA requires four
additional pieces of information that
were not available from USCS’s system
in order to make an admissibility
decision for each entry. These data
elements include the FDA Product
Code, FDA country of production,
manufacturer/shipper, and ultimate
consignee. OMB has previously
approved the automated collection of
these four data elements for tobacco
products that filers could provide to
FDA along with other entry-related
information. Providing this information
to FDA results in importers receiving an
FDA admissibility decision more
expeditiously, e.g., the quantity, value,
and Affirmation(s) of Compliance with
Qualifier(s).
Since the inception of the interface
with ACS, FDA’s electronic screening
criteria program has been applied
nationwide. This eliminates issues such
as ‘‘port shopping’’ (attempts to
intentionally slip products through one
FDA port when refused by another, or
filing entries at a port known to receive
a high volume of entries). Every
electronically submitted entry line of
foreign-origin, FDA-regulated product
undergoes automated screening and the
screening criteria can be set to be as
specific or as broad as applicable;
changes are immediately effective. This
capability is of tremendous value in
protecting the public if there is a need
to immediately halt specific product
from entering the United States.
If the data in this collection of
information is not collected, FDA could
not adequately meet its statutory
responsibilities to regulate imported
products, nor control potentially
dangerous products from entering the
U.S. marketplace.
In the Federal Register of November
27, 2013 (78 FR 70951), FDA published
a 60-day notice requesting public
comment on the proposed collection of
information. No comments were
received.
FDA estimates the burden of this
collection of information as follows:
E:\FR\FM\13MRN1.SGM
13MRN1
14256
Federal Register / Vol. 79, No. 49 / Thursday, March 13, 2014 / Notices
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
FDA imported products
Number of
responses per
respondent
Average
burden per
response
Total annual
responses
Total
hours
Non-Tobacco ........................................................................
Tobacco ...............................................................................
3,406
330
1,089
68
3,709,134
22,440
2 0.14
2 0.14
519,279
3,142
Total ..............................................................................
........................
........................
........................
........................
522,421
1 There
2 (8
are no capital costs or operating and maintenance costs associated with this collection of information.
minutes).
The hourly burden for this
information collection is based on
FDA’s averaging of data obtained during
a survey of nine representative filers
nationwide and FDA’s experience. For
purposes of comparison of hourly
burden, the filers also were requested to
provide the same information with
regard to filing entries manually. FDA
felt that the average time for completing
either electronic or manual entries was
very similar.
Based on data collected by FDA’s
survey of nine filers and its experience,
the total annual burden to the import
community to submit information
electronically for 3,731,574 average
annual responses was 522,421 hours.
The previously OMB-approved hours
per response (0.14 hours) are expected
to remain the same.
This burden includes the time FDA
estimates it will take respondents to
compile and provide documents to FDA
for those entries where FDA cannot
make an admissibility decision based on
the electronic data alone. Based on the
survey of nine filers and FDA’s past
experience, FDA estimates that there
will be no additional costs to provide
import data electronically to FDA, as
filers already have equipment and
software in place to enable them to
provide data to USCS via the automated
system. Therefore, no additional
software or hardware need be developed
or purchased to enable filers to file the
FDA data elements at the same time
they file entries electronically with
USCS.
Dated: March 7, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
TKELLEY on DSK3SPTVN1PROD with NOTICES
[FR Doc. 2014–05516 Filed 3–12–14; 8:45 am]
BILLING CODE 4160–01–P
VerDate Mar<15>2010
17:33 Mar 12, 2014
Jkt 232001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment
Request; Evaluation of National
Institutes of Health International
Bilateral Programs (FIC, NCI, NIAAA,
NIAID, NICHD, NIDA, NINDS, NIMH,
OAR)
In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Cancer Institute (NCI),
National Institutes of Health (NIH), will
publish periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Written comments and/or suggestions
from the public and affected agencies
are invited on one or more of the
following points: (1) Whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimize the
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
To Submit Comments and For Further
Information: To obtain a copy of the
data collection plans and instruments,
submit comments in writing, or request
more information on the proposed
project, contact: Julie Schneider,
Program Director, Center for Global
Health, National Cancer Institute, 9609
Medical Center Dr., RM 3W564,
Rockville, MD 20850 or call non-tollfree number 240–276–5795 or Email
SUMMARY:
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
your request, including your address to:
schneidj@mail.nih.gov. Formal requests
for additional plans and instruments
must be requested in writing.
DATES: Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Proposed Collection: Evaluation of
National Institutes of Health
International Bilateral Programs (FIC,
NCI, NIAAA, NIAID, NICHD, NIDA,
NIMH, NINDS, OAR), 0925–NEW,
National Cancer Institute (NCI),
National Institutes of Health (NIH).
Need and Use of Information
Collection: This submission is a request
for OMB to approve the Evaluation of
National Institutes of Health (NIH)
International Bilateral Programs for
three years. The bilateral awards are
made through the Funding Opportunity
Announcement mechanism and
administrative supplements, meaning
they are funded by set-aside funds that
are separate from the general pool of
research program grant funds used to
support investigator initiated research at
NIH. The bilateral programs to be
evaluated are the U.S.-China Program
for Biomedical Research Cooperation,
U.S.—India Bilateral Collaborative
Research Partnerships on the Prevention
of HIV/AIDS and Co-morbidities, U.S.Russia Bilateral Collaborative Research
Partnerships on the Prevention and
Treatment of HIV/AIDS and Comorbidities, and U.S.-South Africa
Program for Collaborative Biomedical
Research. These programs are funded
and administered by various
combinations of the following institutes:
Fogarty International Center (FIC), the
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development (NICHD), National Cancer
Institute (NCI), National Institute on
Alcohol Abuse and Alcoholism
(NIAAA), National Institute for Allergy
and Infectious Diseases (NIAID),
National Institute on Drug Abuse
(NIDA), National Institute of Mental
Health (NIMH), National Institute of
Neurological Disorders and Stroke
E:\FR\FM\13MRN1.SGM
13MRN1
Agencies
[Federal Register Volume 79, Number 49 (Thursday, March 13, 2014)]
[Notices]
[Pages 14255-14256]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-05516]
[[Page 14255]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-1423]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Importer's Entry
Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by April
14, 2014.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0046.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville,
MD 20850, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Importer's Entry Notice--(OMB Control Number 0910-0046)--Extension
Section 801 of the Federal Food, Drug, and Cosmetic Act (the FD&C
Act) (21 U.S.C. 381) charges the Secretary of Health and Human
Services, through FDA, with the responsibility of assuring foreign-
origin, FDA-regulated foods, drugs, cosmetics, medical devices,
radiological health, and tobacco products offered for import into the
United States meet the same requirements of the FD&C Act as do domestic
products, and for preventing products from entering the country if they
are not in compliance. The discharge of this responsibility involves
close coordination and cooperation between FDA headquarters and field
inspectional personnel and the U.S. Customs Service (USCS), as the USCS
is responsible for enforcing the revenue laws covering the very same
products.
This collection of information gathers data for FDA-regulated
products being imported into the United States and is being used by FDA
to review and prevent imported products from entering the United States
if the products do not meet the same requirements of the FD&C Act as
domestic products.
Until October 1995, importers were required to file manual entries
on OMB-approved forms that were accompanied by related documents. FDA
did away with use of the paper forms effective October 1, 1995, to
eliminate duplicity of information and to reduce the paperwork burden
both on the import community and FDA. FDA then implemented an automated
nationwide entry processing system, which enabled FDA to more
efficiently obtain and process the information it requires to fulfill
its regulatory responsibility.
Most of the information FDA requires to carry out its regulatory
responsibilities under section 801 is already provided electronically
by filers to USCS. Because USCS relays this data to FDA using an
electronic interface, the majority of data submitted by the entry filer
need be completed only once.
At each U.S. port of entry (seaport, landport, and airport) where
foreign-origin, FDA-regulated products are offered for import, FDA is
notified through USCS's Automated Commercial System (ACS) by the
importer (or his/her agent) of the arrival of each entry. Following
such notification, FDA reviews relevant data to ensure the imported
product meets the standards as required for domestic products, decides
on the admissibility of the imported product, and informs the importer
and USCS of its decision. A single entry frequently contains multiple
lines of different products. FDA may authorize products listed on
specific lines to enter the United States unimpeded, while other
products listed in the same entry may be held pending further FDA
review/action.
All entry data pass through a screening criteria program resident
on a USCS computer. This screening program was developed and is
maintained by FDA. This electronic screening criteria module makes the
initial screening decision on every entry of foreign-origin, FDA-
regulated product. Almost instantaneously after the entry is filed, the
filer receives FDA's admissibility decision for each entry, i.e., ``MAY
PROCEED'' or ``FDA REVIEW.''
In addition to the information collected by USCS, FDA requires four
additional pieces of information that were not available from USCS's
system in order to make an admissibility decision for each entry. These
data elements include the FDA Product Code, FDA country of production,
manufacturer/shipper, and ultimate consignee. OMB has previously
approved the automated collection of these four data elements for
tobacco products that filers could provide to FDA along with other
entry-related information. Providing this information to FDA results in
importers receiving an FDA admissibility decision more expeditiously,
e.g., the quantity, value, and Affirmation(s) of Compliance with
Qualifier(s).
Since the inception of the interface with ACS, FDA's electronic
screening criteria program has been applied nationwide. This eliminates
issues such as ``port shopping'' (attempts to intentionally slip
products through one FDA port when refused by another, or filing
entries at a port known to receive a high volume of entries). Every
electronically submitted entry line of foreign-origin, FDA-regulated
product undergoes automated screening and the screening criteria can be
set to be as specific or as broad as applicable; changes are
immediately effective. This capability is of tremendous value in
protecting the public if there is a need to immediately halt specific
product from entering the United States.
If the data in this collection of information is not collected, FDA
could not adequately meet its statutory responsibilities to regulate
imported products, nor control potentially dangerous products from
entering the U.S. marketplace.
In the Federal Register of November 27, 2013 (78 FR 70951), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
FDA estimates the burden of this collection of information as
follows:
[[Page 14256]]
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of Average
FDA imported products Number of responses per Total annual burden per Total hours
respondents respondent responses response
----------------------------------------------------------------------------------------------------------------
Non-Tobacco..................... 3,406 1,089 3,709,134 \2\ 0.14 519,279
Tobacco......................... 330 68 22,440 \2\ 0.14 3,142
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 522,421
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
\2\ (8 minutes).
The hourly burden for this information collection is based on FDA's
averaging of data obtained during a survey of nine representative
filers nationwide and FDA's experience. For purposes of comparison of
hourly burden, the filers also were requested to provide the same
information with regard to filing entries manually. FDA felt that the
average time for completing either electronic or manual entries was
very similar.
Based on data collected by FDA's survey of nine filers and its
experience, the total annual burden to the import community to submit
information electronically for 3,731,574 average annual responses was
522,421 hours. The previously OMB-approved hours per response (0.14
hours) are expected to remain the same.
This burden includes the time FDA estimates it will take
respondents to compile and provide documents to FDA for those entries
where FDA cannot make an admissibility decision based on the electronic
data alone. Based on the survey of nine filers and FDA's past
experience, FDA estimates that there will be no additional costs to
provide import data electronically to FDA, as filers already have
equipment and software in place to enable them to provide data to USCS
via the automated system. Therefore, no additional software or hardware
need be developed or purchased to enable filers to file the FDA data
elements at the same time they file entries electronically with USCS.
Dated: March 7, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-05516 Filed 3-12-14; 8:45 am]
BILLING CODE 4160-01-P